Apellis Pharmaceuticals Inc Insider Sells Shares
Chief Business & Strat Officer Mark Delong of Apellis Pharmaceuticals Inc (NASDAQ:APLS) has sold 1,631 shares of the company on January 16, 2024, according to a recent SEC Filing. The transaction was executed at a stock price of $66.81, resulting in a total sale amount of approximately $108,972.11.
Apellis Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases through the inhibition of the complement system at the level of C3.
Over the past year, the insider has sold a total of 1,762 shares of Apellis Pharmaceuticals Inc and has not made any purchases of the stock. The recent sale by the insider is part of a trend observed over the past year, where there have been no insider buys and 59 insider sells.
On the date of the insider's recent sale, Apellis Pharmaceuticals Inc had a market capitalization of $7.811 billion.
The stock's price-to-GF-Value ratio was 0.46, with a GF Value of $144.67, indicating that the stock is considered a Possible Value Trap, Think Twice according to GuruFocus's valuation model. The GF Value is determined by historical trading multiples, a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
